Financials in USD. Standardized financial statements.
A compact view of how Celularity Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $26.55M | $54.22M | $22.77M | $17.98M | $21.34M | $14.28M | $21.15M | $17.55M |
| Revenue Growth? | -51.0% | +138.1% | +26.7% | -15.7% | +49.4% | -32.5% | +20.5% | 0.0% |
| Cost of Revenue? | $6.36M | $14.99M | $16.02M | $19.66M | $9.65M | $4.93M | $6.32M | $6.55M |
| Gross Profit? | $20.19M | $39.23M | $6.75M | -$1.69M | $11.68M | $9.35M | $14.82M | $11.00M |
| Gross Margin? | +76.0% | +72.4% | +29.7% | -9.4% | +54.8% | +65.5% | +70.1% | +62.7% |
| Operating Expenses? | $81.50M | $77.59M | $199.04M | $23.91M | $120.74M | $161.27M | $278.95M | $1,098 |
| Operating Income? | -$61.31M | -$38.36M | -$192.29M | -$25.60M | -$109.06M | -$151.93M | -$264.13M | -$1,098 |
| EBITDA? | -$77.66M | -$43.71M | -$183.95M | -$138.83M | -$88.11M | -$202.41M | -$70.98M | -$1,098 |
| Income Before Tax | -$91.71M | -$57.89M | -$196.28M | $14.21M | -$100.10M | -$212.93M | -$267.99M | -$1,098 |
| Income Tax Expense | $3,000 | $0 | $10,000 | $13,000 | $20,000 | -$4.70M | -$56.11M | $0 |
| Net Income? | -$91.80M | -$57.89M | -$196.29M | $14.19M | -$100.12M | -$208.23M | -$211.88M | -$1,098 |
| EPS? | $-3.59 | $-2.64 | $-11.02 | $1.01 | $-7.87 | $-113.06 | $-88.75 | $0.00 |
| Diluted EPS? | $-3.59 | $-2.64 | $-11.02 | $0.95 | $-7.87 | $-113.06 | $-88.75 | $0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality